Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors
摘要:
A series of 3,3-disubstituted pyrrolidine monoamine triple reuptake inhibitors were discovered. Analogues with low nanomolar potency, good human in vitro microsomal stability and in vitro permeability, and low drug-drug interaction potential are described. One example showed in vivo anti-depressant-like effects in the mouse tail suspension assay with a minimum effective dose of 30 mg/kg ip. (C) 2008 Elsevier Ltd. All rights reserved.
[EN] PYRROLIDINYL DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE PYRROLIDINYLE ET LEURS UTILISATIONS
申请人:HOFFMANN LA ROCHE
公开号:WO2009115427A1
公开(公告)日:2009-09-24
The invention relates to 3,3 disubstituted pyrrole derivatives useful for treatment of diseases associated with monoamine reuptake inhibitors.Also provided pharmaceutical compositions, methods of using, and methods of preparing the compounds.
The invention relates to 3,3 disubstituted pyrrole derivatives useful for treatment of diseases associated with monoamine reuptake inhibitors. Also provided pharmaceutical compositions, methods of using, and methods of preparing the compounds.
[EN] METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION<br/>[FR] MÉTHODES DE TRAITEMENT DE SYMPTÔMES D'UNE INFECTION À CORONAVIRUS
申请人:ACCENCIO LLC
公开号:WO2022056115A1
公开(公告)日:2022-03-17
The present disclosure relates to methods of treating at least one symptom of a coronavirus infection, or preventing an acute inflammatory response, e.g., a cytokine storm in a coronavirus patient, in particular a SARS-CoV-19 patient, by administering an angiontensin converting enzyme-2 (ACE2) modulator.